Pharmaceutical News

RSS

New antimicrobial strategies show how science is tackling rising drug resistance

This narrative review in the British Journal of Biomedical Science examines emerging and recently approved therapeutic strategies to combat antimicrobial resistance, spanning new antibiotics, microbiome interventions, natural products, predatory bacteria, vaccines, and advanced technologies. It highlights both promising innovations and the urgent need for sustained global investment as many approaches remain in early development.

24 Feb 2026

Tirzepatide activates brown fat, boosting metabolism beyond appetite control

Tirzepatide is one of the drugs that has revolutionized the treatment of obesity and other conditions such as diabetes in recent years.

24 Feb 2026

Osteoporosis drugs show promise against toxic iron accumulation

Researchers at the University of São Paulo (USP) in Brazil have discovered that two osteoporosis drugs (etidronate and tiludronate) may combat diseases caused by iron accumulation in the body.

23 Feb 2026

Study finds widespread off-label use of antipsychotics among older people

The use of antipsychotic medications for purposes other than those officially approved is common among older adults in Finland.

23 Feb 2026

Biochar adsorption of antibiotics depends on molecular structure

Antibiotic pollution in water is a growing global concern, as residues from human medicine, livestock production, and aquaculture can persist in the environment and contribute to the spread of antibiotic resistance.

22 Feb 2026

Mounjaro ingredient shows promise in lowering alcohol consumption

For the first time, researchers show that tirzepatide - the active ingredient in the diabetes and weight-loss drug Mounjaro - reduces alcohol intake as well as relapse-like behaviors in rats and mice.

20 Feb 2026

Should drug companies be advertising to consumers?

Tamar Abrams had a lousy couple of years in 2022 and '23. Both her parents died; a relationship ended; she retired from communications consulting.

20 Feb 2026

Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk

An individualized neoantigen mRNA vaccine was tested in patients with early-stage triple-negative breast cancer and showed feasibility, safety, and strong T cell immune responses. Long-term follow-up suggested durable immune memory with encouraging relapse-free outcomes, though controlled trials are needed to confirm clinical benefit.

19 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

High-cost rare disease drugs challenge Norwegian health priorities

New medical developments make it possible to treat an increasing number of severe and rare diseases with novel, high-cost pharmaceuticals.

19 Feb 2026

Monthly produce prescriptions do not improve blood sugar

Findings from a study on produce prescriptions show no significant improvement in blood sugar control, emphasizing the importance of addressing food insecurity.

19 Feb 2026

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026

Oral weight loss ingredient may have adverse biological effects for the gut and beyond

A new study from Adelaide University is turning a spotlight on those tablet versions, finding that the absorption-enhancing ingredient salcaprozate sodium (SNAC) may have measurable adverse biological effects for the gut and beyond.

17 Feb 2026

Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, inflammatory, mitochondrial, and proteostasis pathways. Evidence from mechanistic, preclinical, and early clinical studies suggests potential neuroprotective effects, but definitive disease-modifying benefit remains unproven.

17 Feb 2026

Short-duration psychedelic therapy shows promise for major depression treatment

A phase IIa randomized trial found that intravenous dimethyltryptamine (DMT) with structured psychological support produced rapid reductions in depressive symptoms in adults with major depressive disorder. Improvements were statistically significant versus placebo at two weeks, with mostly mild-to-moderate adverse events and the need for larger confirmatory studies emphasized.

17 Feb 2026

Cornell study finds existing drug could boost liver cancer immunotherapy

Immunotherapy – which activates the body's own immune system to kill cancer cells – has not worked well against a rare and fatal liver cancer, but a new Cornell University study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment.

17 Feb 2026